

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPAL600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Caplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Caplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Caplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Caplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Caplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment

NEWS 35 JAN 28 MEDLINE and LMedLINE reloaded with enhancements  
NEWS 36 FEB 08 STN Express, Version 8.3, now available

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:21:11 ON 11 FEB 2008

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:21:23 ON 11 FEB 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 FEB 2008 HIGHEST RN 1002565-97-0  
DICTIONARY FILE UPDATES: 10 FEB 2008 HIGHEST RN 1002565-97-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\QUERIES\105274611.str



```

chain nodes :
7 8 9 10 11
ring nodes :
1 2 3 4 5 6 12 13 14 15 16 17
chain bonds :
2-9 3-10 5-7 6-8 7-11 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
2-9 5-7 6-8 7-11 11-12 12-13 12-17 13-14 14-15 15-16 16-17
exact bonds :
3-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS


```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 10:21:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0
```

L2 0 SEA SSS SAM L1

```
=> s l1 full
FULL SEARCH INITIATED 10:21:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 107 TO ITERATE
```

```
100.0% PROCESSED 107 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01
```

L3 4 SEA SSS FUL L1

```
=> s l3 and caplus/lc
56036497 CAPLUS/LC
L4 4 L3 AND CAPLUS/LC
```

```
=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
                        ENTRY SESSION
FULL ESTIMATED COST 183.51 183.72
```

```
FILE 'CAPLUS' ENTERED AT 10:21:48 ON 11 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 11 Feb 2008 VOL 148 ISS 7
FILE LAST UPDATED: 10 Feb 2008 (20080210/ED)
```


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s l4
L5 6 L4
```

```
=> d ibib abs hitstr 1-6
```


15 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS ON STM  
 ACCESSION NUMBER: 2007810510 CAPLUS  
 DOCUMENT NUMBER: 147395925  
 TITLE: Convergent Approach for Commercial Synthesis of Gefitinib and Erlotinib  
 AUTHOR(S): Chandregowda, Venkateshappa; Rao, Gudapati Venkateswara; Reddy, Gokulapalli Chandrasekhara  
 CORPORATE SOURCE: Vittal Mallappa Scientific Research Foundation, Bangalore, 560004, India  
 SOURCE: Organic Process Research & Development (2007), 11(5), 813-826  
 CODING SYSTEM: ISSN: 1083-6160  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: English  
 LANGUAGE: English  
 GI




AB An efficient, economical and large-scale convergent synthesis of epidermal growth factor receptor tyrosine kinase inhibitors gefitinib (I, Iressa) and erlotinib (II, Tarceva), which are approved by the U.S. FDA for the treatment of non-small-cell lung cancer, is described. The formation of 4-aminoquinazolinones was achieved in a simple one-pot reaction of suitable formamide intermediates and substituted anilines involving Danzoh rearrangement, thereby avoiding the need to make quinoxalin-4(3H)-one intermediates which require large eqpt. inputs. Using this process, I was prepared with overall yield of 64% from 4-methoxy-5-[3-(4-morpholinyl)propoxy]-2-nitrobenzonitrile and II in 63% yield from 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile on a multigram scale.  
 IT 675126-53-3P  
 RI: ITC (Industrial manufacture); RCT (Reactant or reagent)  
 Preparation; PREP (Preparation); RACT (Reactant or reagent)  
 and heterocyclization of 1-(morpholinopropoxy)phenylformamide with chlorofluoroaniline in the large-scale con. preparation of gefitinib and erlotinib lung cancer treatment drugs]

15 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)  
 REFERENCES COVER: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS  
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE EE


15 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)  
 RI: ITC (Industrial manufacture); RCT (Reactant or reagent)  
 Preparation; PREP (Preparation); RACT (Reactant or reagent)  
 and heterocyclization of 1-(morpholinopropoxy)phenylformamide with chlorofluoroaniline in the large-scale con. preparation of gefitinib and erlotinib lung cancer treatment drugs]



IT 675126-27-92  
 RI: ITC (Industrial manufacture); RCT (Reactant or reagent)  
 Preparation; PREP (Preparation); RACT (Reactant or reagent)  
 and heterocyclization of 1-(morpholinopropoxy)phenylformamide with chlorofluoroaniline in the large-scale con. preparation of gefitinib and erlotinib lung cancer treatment drugs]




IT 675126-26-8  
 RI: ITC (Industrial manufacture); RCT (Reactant or reagent)  
 Preparation; PREP (Preparation); RACT (Reactant or reagent)  
 and heterocyclization of 1-(morpholinopropoxy)phenylformamide with chlorofluoroaniline in the large-scale con. preparation of gefitinib and erlotinib lung cancer treatment drugs]



15 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS ON STM  
 ACCESSION NUMBER: 2007131109 CAPLUS  
 DOCUMENT NUMBER: 146421938  
 TITLE: One-pot conversion of 2-nitrobenzonitriles to quinazolin-4(3H)-ones and synthesis of gefitinib and erlotinib hydrochloride  
 AUTHOR(S): Chandregowda, Venkateshappa; Rao, Gudapati Venkateswara; Reddy, Gokulapalli Chandrasekhara  
 CORPORATE SOURCE: Vittal Mallappa Scientific Research Foundation, Bangalore, 560004, India  
 SOURCE: Organic Process Research & Development (2007), 11(1), 39-48  
 CODING SYSTEM: ISSN: 1083-6160  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: English  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 146421938  
 GI



AB A simple and efficient one-pot conversion of 2-nitrobenzonitriles to quinazolin-4(3H)-ones involving reduction, cyclization, hydrolysis and cyclization is reported. E.g., Quinoxalin-4(3H)-one derivative I was prepared with 85% yield by reacting the corresponding 2-nitrobenzonitrile II with hydrazine using FeCl<sub>3</sub> in MeOH/EtO followed by treating the reaction mixture with formic acid and HCl. These quinazolinones have been used for making in economical way the anticancer drug mole. gefitinib (Iressa) and erlotinib (Tarceva).  
 IT 675126-26-8P  
 RI: ITC (Industrial manufacture); RCT (Reactant or reagent)  
 Preparation; PREP (Preparation); RACT (Reactant or reagent)  
 and heterocyclization of 1-(morpholinopropoxy)phenylformamide with chlorofluoroaniline in the large-scale con. preparation of gefitinib and erlotinib lung cancer treatment drugs]




15 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)


REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

15 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STM

ACCESSION NUMBER: 2004-625376 CAPLUS  
DOCUMENT NUMBER: 145249168  
TITLE: Synthesis of [11C]lissaza as a new potential PET  
CANCER imaging agent for epidermal growth factor receptor tyrosine kinase  
AUTHOR(S): Wang, Ji-Qiang; Gao, Minghang; Miller, Kathy D.; Sledge, George M.; Thong, Qi-Ruang  
CORPORATE SOURCE: Department of Radiology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA  
SOURCE: Microscopic & Molecular Chemistry Letters (2006), 16(15), 4102-4106  
CUBA: (WCLAB); ISSN: 0960-894X  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 145249168  
AB Lissaza (pefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]lissaza was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40% radiochem. yield with 4.0-4.5 Ci/mmol specific activity at end of bombardment (EOB).  
IT 675126-26-9 CAPLUS  
Ela RCT (Reagent); STM (Synthetic preparation); PREP (Preparation); NACT (Reagent or reagent)  
[Preparation of carbon-11 lissaza as PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase]  
IN 675126-26-9 CAPLUS  
CS Bezonitilide, 4-methoxy-5-[3-(4-morpholinyl)propyl]-2-nitro- (CA INDEX NAME)



IN 675126-27-9 CAPLUS  
CS Bezonitilide, 2-amino-4-methoxy-5-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



15 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

15 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STM

ACCESSION NUMBER: 2005-689694 CAPLUS  
DOCUMENT NUMBER: 143194029  
TITLE: An improved process for preparation of gefitinib, useful as antitumor agent  
INVENTOR(S): Jyoti Bhand, Kamandeshyulla Palla Reddy, Muddeanna, Nagaswara Rao, Bolepalli Venkatesh Choudhary, Manapam  
PATENT ASSIGNEE(S): NCT Int. Appl., 53 pp.  
SOURCE: Patent  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070999	A1	20050804	WO 2004-10223	20040717
WI	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, EE, EG, ES, FI, GB, GR, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LT, LU, LV, MA, MD, ME, MG, MK, MN, MU, MY, NZ, NI, NO, NR, OM, OS, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SI, SK, SM, SV, TJ, TM, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW			
HA	HA, GB, GM, HE, IE, IS, MA, MC, MD, ME, MG, MK, MU, MY, NZ, NI, NO, NR, OM, OS, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SI, SK, SM, SV, TJ, TM, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW			
IN 2004080044	A	20040526	IN 2004-CH66	20040212
PRIORITY APPL. INFO.:			IN 2004-CH66	A 20040212
OTHER SOURCE(S):			CASREACT 143194029	
CI				



O=C1NC(=O)c2cc(OC3CCOCC3)c(C#N)cc21

REFERENCE COURT: 0 THERE ARE 0 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

33.66

217.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.80

-4.80

STN INTERNATIONAL LOGOFF AT 10:22:53 ON 11 FEB 2008